ESTRO 2025 - Abstract Book

S1744

Clinical – Upper GI

ESTRO 2025

Conclusion: SABR is an effective, safe, and feasible treatment modality for patients with recurrent HCC, demonstrating high local control rates and minimal toxicity. These findings suggest that SABR could be considered as a primary therapeutic approach in future studies involving patients with HCC, particularly in cases where other local ablative therapies have failed.

Keywords: HCC, SABR, Local-control

407

Digital Poster Evaluation of the benefits of radio-chemotherapy in locally advanced pancreatic cancer: a multicenter cohort study Loic Ah-thiane 1 , Pierre Tremolieres 2 , Jessica Serrand 3 , Camille Berthet 4 , Pauline Lemoine 5 , Stéphane Supiot 1 , Valentine Guimas 1 , Elodie Martin 6 , Emmanuel Rio 1 1 Radiotherapy, Western Cancer Institute, Nantes, France. 2 Radiotherapy, Western Cancer Institute, Angers, France. 3 Radiotherapy, Leon Berard Center, Lyon, France. 4 Radiotherapy, Eugene Marquis Center, Rennes, France. 5 Radiotherapy, Oscar Lambret Institute, Lille, France. 6 Biostatistics, Western Cancer Institute, Nantes, France Purpose/Objective: Locally advanced pancreatic cancer (LAPC) remains a devastating disease with limited therapeutic options and poor survival outcomes. While chemotherapy is the standard first-line treatment, the role of consolidation (chemo)radiotherapy ((C-)RT) remains controversial. This large multicenter cohort study aimed to evaluate the efficacy and safety of (C-)RT following induction chemotherapy in patients with LAPC.